Triadopathies: An Emerging Class of Skeletal Muscle Diseases

Neurotherapeutics

Volumn 11, Issue 4, 2014, Pages 773-785

  Dowling, James J ^a,b,c   Lawlor, Michael W ^d   Dirksen, Robert T ^e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

congenital myopathies; Excitation contraction coupling; malignant hyperthermia; RYR1; triad

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ACETYLCYSTEINE; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CALPAIN 3; DANTROLENE; DYSTROPHIN; HALOTHANE; ISOFLURANE; MYOTONIC DYSTROPHY PROTEIN KINASE; RYANODINE RECEPTOR; RYANODINE RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SELENOPROTEIN; SEVOFLURANE; CCDC78 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MUSCLE PROTEIN; SEPN1 PROTEIN, HUMAN;

AMERICAN INDIAN; BECKER MUSCULAR DYSTROPHY; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CALPAINOPATHY; CCDC78 GENE; CENTRONUCLEAR MYOPATHY; DISABILITY; DUCHENNE MUSCULAR DYSTROPHY; DYSFERLINOPATHY; DYSTROPHINOPATHY; ELECTRON MICROSCOPY; EXCITATION CONTRACTION COUPLING; EXON SKIPPING; GENE; GENE FUNCTION; GENE MUTATION; GENE SILENCING; HAPLOINSUFFICIENCY; HEART FAILURE; HUMAN; INDUCED HYPOTHERMIA; MALIGNANT HYPERTHERMIA; MULTIMINICORE DISEASE; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYALGIA; MYOPATHY; MYOTONIC DYSTROPHY TYPE I; NATIVE AMERICAN MYOPATHY; NONHUMAN; NONSENSE MUTATION; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RHABDOMYOLYSIS; SARCOGLYCANOPATHY; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; TRANSVERSE TUBULAR SYSTEM; TRIADOPATHY; ANIMAL; GENETICS; METABOLISM; MUSCLE DISEASE;

ANIMALS; HUMANS; MALIGNANT HYPERTHERMIA; MICROTUBULE-ASSOCIATED PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MUSCULAR DYSTROPHIES; MYOPATHIES, STRUCTURAL, CONGENITAL; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SELENOPROTEINS;

EID: 84919781500     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0300-3     Document Type: Review

References (111)

1. Engel A, Franzini-Armstrong C. Myology: basic and clinical. 3rd ed. McGraw-Hill, New York, 2004.
2. Melzer W, Herrmann-Frank A, Luttgau HC. The role of Ca2+ ions in excitation-contraction coupling of skeletal muscle fibres. Biochim Biophys Acta 1995;1241:59-116.
3. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006;33:715-731.
4. Nance JR, Dowling JJ, Gibbs EM, Bonnemann CG. Congenital myopathies: an update. Curr Neurol Neurosci Rep 2012;12:165-174.
5. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.
6. Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant hyperthermia susceptibility. In: Pagon RA, Adam MP, Bird TD, et al. (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2014; 2003 Dec 19 [updated 2013 Jan 31].
7. Denborough M. Malignant hyperthermia. Lancet 1998;352:1131-1136.
8. McCarthy EJ. Malignant hyperthermia: pathophysiology, clinical presentation, and treatment. AACN Clin Issues 2004;15:231-237.
9. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110:498-507.
10. Donnelly AJ. Malignant hyperthermia. Epidemiology, pathophysiology, treatment. AORN J 1994;59:393-395.
11. Gonsalves SG, Ng D, Johnston JJ, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology 2013;119:1043-1053.
12. Stowell KM. DNA testing for malignant hyperthermia: the reality and the dream. Anesth Analg 2014;118:397-406.
13. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-989.
14. Carpenter D, Ringrose C, Leo V, et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet 2009;10:104.
15. Yarotskyy V, Dirksen RT. Cav1.1 in malignant hyperthermia. In: Weiss N, Koschak A (eds) Pathologies of calcium channels. Springer-Verlag, Berlin, 2014.
16. Kim JH, Jarvik GP, Browning BL, et al. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology 2013;119:1054-1065.
17. Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009;109:1065-1069.
18. Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA 2001;286:168-169.
19. Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013;23:540-548.
20. Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F. 182nd ENMC International Workshop: RYR1-related myopathies, 15–17th April 2011, Naarden, The Netherlands. Neuromuscul Disord 2012;22:453-462.
21. Jungbluth H. Central core disease. Orphanet J Rare Dis 2007;2:25.
22. Jungbluth H. Multi-minicore disease. Orphanet J Rare Dis 2007;2:31.
23. Wilmshurst JM, Lillis S, Zhou H, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 2010;68:717-726.
24. Clarke NF, Waddell LB, Cooper ST, et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mutat 2010;31:E1544-E1550.
25. Klein A, Lillis S, Munteanu I, et al. Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat 2012;33:981-988.
26. Zhou H, Lillis S, Loy RE, et al. Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2010;20:166-173.
27. Illingworth MA, Main M, Pitt M, et al. RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine. Neuromuscul Disord 2014;24:707-712.
28. Dowling JJ, Lillis S, Amburgey K, et al. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2011;21:420-427.
29. Jungbluth H, Lillis S, Zhou H, et al. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2009;19:344-347.
30. Amburgey K, Bailey A, Hwang JH, et al. Genotype-phenotype correlations in recessive RYR1-related myopathies. Orphanet J Rare Dis 2013;8:117.
31. Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008;8:319-326.
32. Messina S, Hartley L, Main M, et al. Pilot trial of salbutamol in central core and multi-minicore diseases. Neuropediatrics 2004;35:262-266.
33. Dowling JJ, Arbogast S, Hur J, et al. Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Brain 2012;135:1115-1127.
34. Andersson DC, Marks AR. Fixing ryanodine receptor Ca leak – a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mechan 2010;7:e151-e157.
35. Loy RE, Lueck JD, Mostajo-Radji MA, Carrell EM, Dirksen RT. Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy. PloS One 2012;7:e49757.
36. Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol 2011;70:662-665.
37. Maggi L, Scoto M, Cirak S, et al. Congenital myopathies–clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord 2013;23:195-205.
38. Takekura H, Nishi M, Noda T, Takeshima H, Franzini-Armstrong C. Abnormal junctions between surface membrane and sarcoplasmic reticulum in skeletal muscle with a mutation targeted to the ryanodine receptor. Proc Natl Acad Sci U S A 1995;92:3381-3385.
39. Hirata H, Watanabe T, Hatakeyama J, et al. Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease. Development 2007;134:2771-2781.
40. Kushnir A, Betzenhauser MJ, Marks AR. Ryanodine receptor studies using genetically engineered mice. FEBS Lett 2010;584:1956-1965.
41. Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008;3:26.
42. Biancalana V, Beggs AH, Das S, et al. Clinical utility gene card for: Centronuclear and myotubular myopathies. Eur J Hum Genet 2012;20.
43. Laporte J, Hu LJ, Kretz C, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175-182.
44. Das S, Dowling J, Pierson CR. X-linked centronuclear myopathy. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2014. 2002 [updated 2011 Oct 6].
45. Bitoun M, Maugenre S, Jeannet PY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005;37:1207-1209.
46. Bohm J, Biancalana V, Dechene ET, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012;33:949-959.
47. Nicot AS, Toussaint A, Tosch V, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007;39:1134-1139.
48. Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 2013;81:1205-1214.
49. Dowling JJ. Titin and centronuclear myopathy: The tip of the iceberg for TTN-ic mutations? Neurology 2013;81:1189-1190.
50. Durieux AC, Prudhon B, Guicheney P, Bitoun M. Dynamin 2 and human diseases. J Mol Med 2010;88:339-350.
51. Koutsopoulos OS, Kretz C, Weller CM, et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. Eur J Hum Genet 2013;21:637-642.
52. Dowling JJ, Vreede AP, Low SE, et al. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet 2009;5:e1000372.
53. Al-Qusairi L, Weiss N, Toussaint A, et al. T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase. Proc Natl Acad Sci U S A 2009;106:18763-18768.
54. Toussaint A, Cowling BS, Hnia K, et al. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies. Acta Neuropathol 2011;121:253-266.
55. Durieux AC, Vignaud A, Prudhon B, et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010;19:4820-4836.
56. Gibbs EM, Davidson AE, Telfer WR, Feldman EL, Dowling JJ. The myopathy-causing mutation DNM2-S619L leads to defective tubulation in vitro and in developing zebrafish. Dis Models Mechan 2014;7:157-161.
57. Smith LL, Gupta VA, Beggs AH. Bridging integrator 1 (Bin1) deficiency in zebrafish results in centronuclear myopathy. Hum Mol Genet 2014;23:3566-3578.
58. Lee E, Marcucci M, Daniell L, et al. Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. Science 2002;297:1193-1196.
59. Al-Qusairi L, Prokic I, Amoasii L, et al. Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways. FASEB J 2013;27:3384-3394.
60. Fetalvero KM, Yu Y, Goetschkes M, et al. Defective autophagy and mTORC1 signaling in myotubularin null mice. Mol Cell Biol 2013;33:98-110.
61. Hnia K, Tronchere H, Tomczak KK, et al. Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. J Clin Invest 2011;121:70-85.
62. Dowling JJ, Joubert R, Low SE, et al. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models. Dis Models Mechan 2012;5:852-859.
63. Robb SA, Sewry CA, Dowling JJ, et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 2011;21:379-386.
64. Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014;6:220–10.
65. Lawlor MW, Armstrong D, Viola MG, et al. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet 2013;22:1525-1538.
66. Gibbs EM, Clarke NF, Rose K, et al. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med 2013;91:727-737.
67. Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008;146A:1832-1841.
68. Horstick EJ, Linsley JW, Dowling JJ, et al. Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy. Nat Commun 2013;4:1952.
69. Nelson BR, Wu F, Liu Y, et al. Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced Ca2+ release and contractility. Proc Natl Acad Sci U S A 2013;110:11881-11886.
70. Jain D, Sharma MC, Sarkar C, et al. Tubular aggregate myopathy: a rare form of myopathy. J Clin Neurosci 2008;15:1222-1226.
71. Misceo D, Holmgren A, Louch WE, et al. A dominant STIM1 mutation causes Stormorken syndrome. Hum Mutat 2014;35:556-564.
72. Nesin V, Wiley G, Kousi M, et al. Activating mutations in STIM1 and ORAI1 cause overlapping syndromes of tubular myopathy and congenital miosis. Proc Natl Acad Sci U S A 2014;111:4197-4202.
73. Bohm J, Chevessier F, Maues De Paula A, et al. Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy. Am J Hum Genet 2013;92:271-278.
74. Feske S. ORAI1 and STIM1 deficiency in human and mice: roles of store-operated Ca2+ entry in the immune system and beyond. Immunol Rev 2009;231:189-209.
75. Dirksen RT. Checking your SOCCs and feet: the molecular mechanisms of Ca2+ entry in skeletal muscle. J Physiol 2009;587:3139-3147.
76. Stathopulos PB, Schindl R, Fahrner M, et al. STIM1/Orai1 coiled-coil interplay in the regulation of store-operated calcium entry. Nat Commun 2013;4:2963.
77. Wei-Lapierre L, Carrell EM, Boncompagni S, Protasi F, Dirksen RT. Orai1-dependent calcium entry promotes skeletal muscle growth and limits fatigue. Nat Commun 2013;4:2805.
78. Yarotskyy V, Protasi F, Dirksen RT. Accelerated activation of SOCE current in myotubes from two mouse models of anesthetic- and heat-induced sudden death. PloS One 2013;8:e77633.
79. Duke AM, Hopkins PM, Calaghan SC, Halsall JP, Steele DS. Store-operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle. J Biol Chem 2010;285:25645-25653.
80. Morgan-Hughes JA. Tubular aggregates in skeletal muscle: their functional significance and mechanisms of pathogenesis. Curr Opin Neurol 1998;11:439-442.
81. Boncompagni S, Protasi F, Franzini-Armstrong C. Sequential stages in the age-dependent gradual formation and accumulation of tubular aggregates in fast twitch muscle fibers: SERCA and calsequestrin involvement. Age 2012;34:27-41.
82. Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012;11:891-905.
83. Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol 2010;67:291-300.
84. Kimura T, Lueck JD, Harvey PJ, et al. Alternative splicing of RyR1 alters the efficacy of skeletal EC coupling. Cell Calcium 2009;45:264-274.
85. Kimura T, Nakamori M, Lueck JD, et al. Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2 + -ATPase in myotonic dystrophy type 1. Hum Mol Genet 2005;14:2189-2200.
86. Tang ZZ, Yarotskyy V, Wei L, et al. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet 2012;21:1312-1324.
87. Fugier C, Klein AF, Hammer C, et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 2011;17:720-725.
88. Morrison LA. Dystrophinopathies. Handb Clin Neurol 2011;101:11-39.
89. Rahimov F, Kunkel LM. The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 2013;201:499-510.
90. Watkins SC, Hoffman EP, Slayter HS, Kunkel LM. Immunoelectron microscopic localization of dystrophin in myofibres. Nature 1988;333:863-866.
91. Capote J, DiFranco M, Vergara JL. Excitation-contraction coupling alterations in mdx and utrophin/dystrophin double knockout mice: a comparative study. Am J Physiol Cell Physiol 2010;298:C1077-C1086.
92. Bellinger AM, Reiken S, Carlson C, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med 2009;15:325-330.
93. Fauconnier J, Thireau J, Reiken S, et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010;107:1559-1564.
94. Goonasekera SA, Lam CK, Millay DP, et al. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest 2011;121:1044-1052.
95. Kirschner J, Lochmuller H. Sarcoglycanopathies. Handb Clin Neurol 2011;101:41-46.
96. Andersson DC, Meli AC, Reiken S, et al. Leaky ryanodine receptors in beta-sarcoglycan deficient mice: a potential common defect in muscular dystrophy. Skelet Muscle 2012;2:9.
97. Amato AA, Brown RH, Jr. Dysferlinopathies. Handb Clin Neurol 2011;101:111-118.
98. Kerr JP, Ward CW, Bloch RJ. Dysferlin at transverse tubules regulates Ca homeostasis in skeletal muscle. Front Physiol 2014;5:89.
99. Kerr JP, Ziman AP, Mueller AL, et al. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane. Proc Natl Acad Sci U S A 2013;110:20831-20836.
100. Gallardo E, Saenz A, Illa I. Limb-girdle muscular dystrophy 2A. Handb Clin Neurol 2011;101:97-110.
101. Kramerova I, Kudryashova E, Wu B, Ottenheijm C, Granzier H, Spencer MJ. Novel role of calpain-3 in the triad-associated protein complex regulating calcium release in skeletal muscle. Hum Mol Genet 2008;17:3271-3280.
102. Castets P, Lescure A, Guicheney P, Allamand V. Selenoprotein N in skeletal muscle: from diseases to function. J Mol Med 2012;90:1095-1107.
103. Arbogast S, Ferreiro A. Selenoproteins and protection against oxidative stress: selenoprotein N as a novel player at the crossroads of redox signaling and calcium homeostasis. Antioxid Redox Signal 2010;12:893-904.
104. Rederstorff M, Castets P, Arbogast S, et al. Increased muscle stress-sensitivity induced by selenoprotein N inactivation in mouse: a mammalian model for SEPN1-related myopathy. PloS One 2011;6:e23094.
105. Castets P, Bertrand AT, Beuvin M, et al. Satellite cell loss and impaired muscle regeneration in selenoprotein N deficiency. Hum Mol Genet 2011;20:694-704.
106. Jungbluth H, Sewry CA, Muntoni F. Core myopathies. Semin Pediatr Neurol 2011;18:239-249.
107. Jurynec MJ, Xia R, Mackrill JJ, et al. Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. Proc Natl Acad Sci U S A 2008;105:12485-12490.
108. Arbogast S, Beuvin M, Fraysse B, Zhou H, Muntoni F, Ferreiro A. Oxidative stress in SEPN1-related myopathy: from pathophysiology to treatment. Ann Neurol 2009;65:677-686.
109. Castets P, Maugenre S, Gartioux C, et al. Selenoprotein N is dynamically expressed during mouse development and detected early in muscle precursors. BMC Develop Biol 2009;9:46.
110. Majczenko K, Davidson AE, Camelo-Piragua S, et al. Dominant mutation of CCDC78 in a unique congenital myopathy with prominent internal nuclei and atypical cores. Am J Hum Genet 2012;91:365-371.
111. Klos Dehring DA, Vladar EK, Werner ME, Mitchell JW, Hwang P, Mitchell BJ. Deuterosome-mediated centriole biogenesis. Develop Cell 2013;27:103-112.